Intangible Assets (Details) - USD ($) $ in Thousands		Jun. 30, 2022	Dec. 31, 2021
Indefinite-Lived Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		$ 29,850	$ 29,850
Finite-Lived Intangible Assets, Accumulated Amortization		20,808	19,886
Intangible Assets, Current		9,042	9,964
Licensing Agreements [Member]
Indefinite-Lived Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	[1]	29,400	29,400
Finite-Lived Intangible Assets, Accumulated Amortization	[1]	20,680	19,780
Intangible Assets, Current	[1]	8,720	9,620
Trademarks and Trade Names [Member]
Indefinite-Lived Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		210	210
Finite-Lived Intangible Assets, Accumulated Amortization		60	50
Intangible Assets, Current		150	160
Customer Relationships [Member]
Indefinite-Lived Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		240	240
Finite-Lived Intangible Assets, Accumulated Amortization		68	56
Intangible Assets, Current		$ 172	$ 184

[1] Prior to the acquisition, Enteris entered into a non-exclusive commercial license agreement (the “License Agreement”) with Cara Therapeutics, Inc. (“Cara”), for oral formulation rights to Enteris’ Peptelligence® technology to develop and commercialize Oral KORSUVA^TM in any indication worldwide, excluding South Korea and Japan. Cara is obligated to pay Enteris certain development, regulatory and tiered commercial milestone payments, as well as low single-digit royalties based on net sales in the licensed territory.